Ixico (IXI)

Sector:

Pharma and Biotech

Index:

FTSE AIM All-Share

 9.75p
   
  • Change Today:
      0.000p
  • 52 Week High: 13.00p
  • 52 Week Low: 6.75p
  • Currency: UK Pounds
  • Shares Issued: 92.67m
  • Volume: 36,242
  • Market Cap: £9.04m
  • Beta: 0.07

Ixico upbeat on breakthrough with AI imaging platform

By Josh White

Date: Wednesday 12 Feb 2025

LONDON (ShareCast) - (Sharecast News) - Ixico announced further validation of its AI-driven imaging platform IXIQ.Ai in Huntington's disease (HD) research on Wednesday, through its collaboration with the Huntington's Disease Imaging Harmonisation (HD-IH) consortium.
The AIM-traded company said the breakthrough strengthened its position in neurological disease analysis, and would open additional revenue opportunities.

It said HD-IH had completed the analysis of over 6,000 MRI datasets, the largest imaging dataset for Huntington's disease to date.

Using that data, Ixico said it had updated the HD-Integrated Staging System (HD-ISS) cut-off values, which guide disease diagnosis, severity assessment, and treatment decisions.

Ixico said its proprietary deep learning algorithm had demonstrated the ability to accurately measure volumetric changes in key brain regions affected by Huntington's disease, providing deeper insights into disease progression.

The firm said it was also working with key opinion leaders to explore the use of brain volume measurements as a surrogate endpoint in clinical trials, potentially offering an alternative to traditional clinical outcomes.

"HD-ISS provides an evidence- based biomarker-based framework for the biological definition of HD," said Ixico's chief scientific officer Robin Wolz.

"The completion of HD-ISS staging cut-off points is an important achievement in the HD-IH consortium."

Wolz said the relevant brain volume measures in a highly accurate and automated tool like IXIQ.Ai allowed "reliable and robust" implementation of the staging system in HD clinical trials.

"With this major milestone, we will focus with our partners to put those measures into clinical trial use and build further evidence towards the use of brain volumetric measures as surrogate endpoints."

At 1356 GMT, shares in Ixico were up 3.83% at 12.2p.

Reporting by Josh White for Sharecast.com.

Email this article to a friend

or share it with one of these popular networks:


Note 1: Prices and trades are provided by Digital Look Corporate Solutions and are delayed by at least 15 minutes.

 

Ixico Market Data

Currency UK Pounds
Share Price 9.75p
Change Today 0.000p
% Change 0.00 %
52 Week High 13.00p
52 Week Low 6.75p
Volume 36,242
Shares Issued 92.67m
Market Cap £9.04m
Beta 0.07

Ixico Star Ratings

Compare performance with the sector and the market.
more star ratings
Key: vs Market vs Sector
Value
5.07% below the market average5.07% below the market average5.07% below the market average5.07% below the market average5.07% below the market average
69.57% above the sector average69.57% above the sector average69.57% above the sector average69.57% above the sector average69.57% above the sector average
Price Trend
27.21% below the market average27.21% below the market average27.21% below the market average27.21% below the market average27.21% below the market average
13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average13.04% above the sector average
Income Not Available
Growth
79.39% below the market average79.39% below the market average79.39% below the market average79.39% below the market average79.39% below the market average
93.75% below the sector average93.75% below the sector average93.75% below the sector average93.75% below the sector average93.75% below the sector average

Ixico Dividends

No dividends found

Trades for 11-Jul-2025

Time Volume / Share Price
11:26 36,242 @ 9.90p

Ixico Key Personnel

CEO Giulio Cerroni
CEO Bram Goorden

Top of Page